For the latest news in
hematology, visit
ASHClinicalNews.org!
CMYK
See Final OS Data Analysis
WH E N M U LTI P L E M YE LOM A RE LA PSE S ,
Don’t put your patient’s
survival at risk
KYPROLIS ® -based regimens (KRd and Kd) reduced the risk of
death by 21% vs Rd and Vd and extended median overall survival
by 7.9 and 7.6 months, respectively 1, * ,†,‡,§
KRd
Kd
AS A TRIPLET THERAPY
8.7-month increase in median PFS 1
9.3-month increase in median PFS 1
26.3 months (KRd) vs 17.6 months (Rd); hazard ratio
(KRd/Rd) = 0.69 (95% CI: 0.57-0.83); two-sided P = 0.0001
7.9-month increase in median OS 1
* 48.3 months (KRd) vs 40.4 months (Rd); hazard ratio
(KRd/Rd) = 0.79 (95% CI: 0.67-0.95); two-sided P = 0.0091
>3x CR or better 1
32% (KRd) vs 9% (Rd)
KRd vs Rd Phase 3 design: N = 792, randomized (1:1), open-label
superiority study comparing KRd vs Rd in relapsed or refractory multiple
myeloma patients who had received 1 to 3 lines of therapy. The primary
endpoint was progression-free survival. Select secondary endpoints
included overall survival and overall response rate. KYPROLIS ® was
discontinued per protocol in the KRd arm after 18 cycles of treatment. 1,2
†
AS A DOUBLET THERAPY
18.7 months (Kd) vs 9.4 months (Vd); hazard ratio
(Kd/Vd) = 0.53 (95% CI: 0.44-0.65); one-sided P < 0.0001
‡
§
7.6-month increase in median OS 1
47.6 months (Kd) vs 40.0 months (Vd); hazard ratio
(Kd/Vd) = 0.79 (95% CI: 0.65-0.96); one-sided P = 0.01
Kd vs Vd Phase 3 design: N = 929, randomized (1:1), open-label
superiority study comparing Kd to Vd in relapsed or refractory
multiple myeloma patients who had received 1 to 3 lines of therapy.
The primary endpoint was progression-free survival. Overall survival
was a prespecifi ed key secondary effi cacy endpoint. 1,3
See more OS results at KYPROLIS-HCP.com
CI = confi dence interval; CR = complete response; Kd = KYPROLIS ® and dexamethasone; KRd = KYPROLIS ® , lenalidomide, and dexamethasone;
OS = overall survival; PFS = progression-free survival; Rd = lenalidomide and dexamethasone; Vd = VELCADE ® (bortezomib) and dexamethasone.
IMPORTANT SAFETY INFORMATION FOR KYPROLIS
Cardiac Toxicities: New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction),
restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of KYPROLIS. Some
events occurred in patients with normal baseline ventricular function. Death due to cardiac arrest has occurred within one day of administration.
Please see additional Important Safety Information on left.
References: 1. KYPROLIS ® (carfi lzomib) prescribing information, Onyx Pharmaceuticals Inc., an Amgen Inc. subsidiary. 2. Siegel DS, Dimopoulos MA, L